Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tscan Therapeutics Inc (NQ: TCRX )

2.535 -0.135 (-5.06%)
Streaming Delayed Price Updated: 1:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,585
Open 2.760
Bid (Size) 2.500 (41)
Ask (Size) 2.570 (1)
Prev. Close 2.670
Today's Range 2.501 - 2.790
52wk Range 1.450 - 3.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+48.25%
+48.25%
1 Month
+15.75%
+15.75%
3 Month
+0.20%
+0.20%
6 Month
-2.12%
-2.12%
1 Year
-6.46%
-6.46%

More News

Read More
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Transition of Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Via Benzinga
Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Closing of Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
TScan Therapeutics Announces Pricing of $140 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Launch of Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.